Therapy of Renal Anemia with Recombinant Human Erythropoietin in Children with End-Stage Renal Disease

Scigalla, P.; Bonzel, K. E.; Bulla, M; Burghard, R.; Dippel, J.; Geisert, J; Leumann, Ernst; Lilien, Tassilo von; Offner, G.; Pisto, K.; Zoellner, K

doi:10.1159/000417899

Cited by 31 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most children treated with haemodialysis are treated with intravenous erythropoietin at the end of dialysis, giving good results [1,3,19]. Good results have also been obtained with the intravenous treatment of children undergoing CAPD or continuous cycling peritoneal dialysis [1,18]; this mode of therapy, however, is not practical.…”

Section: Discussionmentioning

confidence: 99%

Intraperitoneal administration of recombinant human erythropoietin in children on continuous ambulatory peritoneal dialysis

1992

View full text Add to dashboard Cite

In 16 children treated by continuous ambulatory peritoneal dialysis (CAPD) recombinant human erythropoietin was administered intraperitoneally for the treatment of renal anaemia. The mean treatment period was 8.3 months. Mean haemoglobin values increased from 4.9 mmol/l at start of therapy to 6.2 after 6 months. While 11 out of 16 children needed a total of 22 transfusions during the 6 months prior to therapy, no transfusions were needed after initiation of therapy. Patients started with a dose of 300 units/kg per week. After 6 months of therapy, the mean dose was 370 and after 12 months 279 units/kg per week. No major side-effects were observed. The incidence of peritonitis was not increased. We conclude that intraperitoneal administration of erythropoietin is effective in the treatment of renal anaemia in children treated by CAPD.

show abstract

Section: Discussionmentioning

confidence: 99%

Intraperitoneal administration of recombinant human erythropoietin in children on continuous ambulatory peritoneal dialysis

1992

View full text Add to dashboard Cite

show abstract

“…Apart from increasing the risk of exposure to certain infections, transfusions sensitize to histocompatibility antigens diminishing the chances of a successful transplant, lead to iron overload and sometimes cause transfusion reactions. The availability of epoetin alfa (EA), a recombinant human erythropoietin, has been recognized as a revolutionary treatment of anaemia in patients with chronic renal disease [2,5,7,11,12,14,15,20]. However, new problems have arisen with the use of this hormone, such as arterial hypertension, hyperkalaemia, hyperphosphataemia and vascular thrombosis [2,4,5,7,11,12,14,15,20].…”

Section: Offprint Requests To: O H Oetlikermentioning

confidence: 99%

“…The availability of epoetin alfa (EA), a recombinant human erythropoietin, has been recognized as a revolutionary treatment of anaemia in patients with chronic renal disease [2,5,7,11,12,14,15,20]. However, new problems have arisen with the use of this hormone, such as arterial hypertension, hyperkalaemia, hyperphosphataemia and vascular thrombosis [2,4,5,7,11,12,14,15,20]. So far, data on the use of EA in paediatric nephrology are rather limited [2,11,14,18].…”

Section: Offprint Requests To: O H Oetlikermentioning

confidence: 99%

“…However, new problems have arisen with the use of this hormone, such as arterial hypertension, hyperkalaemia, hyperphosphataemia and vascular thrombosis [2,4,5,7,11,12,14,15,20]. So far, data on the use of EA in paediatric nephrology are rather limited [2,11,14,18]. We report our preliminary experience with this hormone in children and adolescents with end-stage renal disease.…”

Section: Offprint Requests To: O H Oetlikermentioning

confidence: 99%

See 1 more Smart Citation

Epoetin alfa in anaemic children or adolescents on regular dialysis

Roduit

et al. 1991

Eur J Pediatr

View full text Add to dashboard Cite

Eighteen patients aged 5-18 years on regular dialysis had a packed cell volume (PCV) less than 0.27. On treatment with epoetin alfa (EA) PCV increased by 0.05 or more in all patients. Iron supplementation was necessary in 13 patients with a ferritinaemia less than 300 micrograms/l before study. During treatment, plasma potassium increased significantly and more vigorous antihypertensive measures were required in 8 patients, 5 of them being already on antihypertensive drugs before EA. Iliofemoral thrombosis occurred in 1 patient 10 days after renal transplant. The data indicate that EA ameliorates the anaemia of chronic renal disease. The main concerns arising during treatment with EA are hyperkalaemia, arterial hypertension and possibly thrombosis.

show abstract

“…Anemia is associated with several physiological disorders in CKD, including decrease of oxygen use and release into the body (HORINA et al, 1993;MAYER et al, 1988;TEEHAN et al, 1989;ROBERTSON et al, 1990;BRAUMANN et al, 1991), increased cardiac output, cardiac area increased, ventricular hypertrophy, angina, congestive heart failure (HARNETT et al, 1995) (WIZEMANN;SCHAFER;KRAMER, 1993), reduction of mental acuity and cognition (WOLCOTT et al, 1989), alteration of menstrual cycles (RAMIREZ et al, 1994) and impairment of immune response (GAFTER et al, 1994). In addition, anemia can retard growth of pediatric patients (SCIGALLA et al, 1989). These abnormalities reduce the quality of life (EVANS; RADER; MANNINEN, 1990) and opportunities for rehabilitation in patients that survived CKD (LOWRIE et al, 1994).…”

Section: Introductionmentioning

confidence: 99%

Evolution of Anemia in Chronic Kidney Disease Patients

PACHTMAN¹,

VIEIRA²,

ABREU³

et al. 2014

Publ. Biologicas

View full text Add to dashboard Cite

Variations in hematocrit and hemoglobin values are constantly checked in patients with chronic kidney disease (CKD) on dialysis in order to monitor the anemia. Anemia and iron deficiency are the most frequent and severe nutritional deficiencies, acting as a cause of morbidity in individuals carrying CKD. The work aimed to monitor the evolution of laboratory parameters of chronic renal patients on dialysis of a clinic in the state of Paraná, Brazil, for twelve months, correlating them with the drug therapy (iron injection and EPO). This is a cross-sectional investigation of quantitative character, whose data were collected from the results of laboratory tests of 108 adult patients. The data showed that at the beginning of the study 86.1% of patients were anemic; the number of patients with serum iron less than 50µg/mL increased 27%, and the number of patients with TSAT<20% increased 129%. The results emphasize the importance of careful evaluation of laboratory values by the health professionals, especially the nephrology clinical team, who deal with patients with CKD through the identification and correction of clinical and laboratory factors that alter the clinical picture of the patient.Keywords: Chronic renal disease. Anemia. Dialysis. RESUMOAs variações nos valores de hematócrito e hemoglobina são constantemente avaliadas em pacientes com doença renal crônica (DRC) em diálise para controlar a anemia. A anemia e deficiência de ferro são mais frequentes e graves deficiências nutricionais, atuando como causa de morbidade em indivíduos portadores de DRC. O trabalho teve como objetivo acompanhar a evolução dos parâmetros laboratoriais de pacientes renais crônicos em diálise de uma clínica no estado do Paraná por doze meses, correlacionandoos com a terapia medicamentosa (injeção de ferro e EPO). Trata-se de uma pesquisa transversal de caráter quantitativo, cujos dados foram coletados dos resultados dos testes laboratoriais de 108 pacientes adultos. Os dados mostraram que, no início do estudo, 86,1% dos pacientes eram anêmicos; o número de pacientes com ferro sérico inferior a 50µg/mL aumentou 27%, e o número de pacientes com TSAT<20% aumentou 129%. Os resultados ressaltam a importância de cuidadosa avaliação dos valores de laboratório

show abstract

Therapy of Renal Anemia with Recombinant Human Erythropoietin in Children with End-Stage Renal Disease

Cited by 31 publications

References 0 publications

Intraperitoneal administration of recombinant human erythropoietin in children on continuous ambulatory peritoneal dialysis

Intraperitoneal administration of recombinant human erythropoietin in children on continuous ambulatory peritoneal dialysis

Epoetin alfa in anaemic children or adolescents on regular dialysis

Evolution of Anemia in Chronic Kidney Disease Patients

Contact Info

Product

Resources

About